← Browse by Condition
Medical Condition

lymphoproliferative disorders

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2, Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for lymphoproliferative disorders sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — lymphoproliferative disorders Clinical Trials

How many clinical trials are currently recruiting for lymphoproliferative disorders?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for lymphoproliferative disorders, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for lymphoproliferative disorders?
lymphoproliferative disorders research spans Phase 1 (1 trial), Phase 2 (3 trials), Phase 3 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a lymphoproliferative disorders clinical trial?
Eligibility criteria for lymphoproliferative disorders trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
3
Phase 3
3
Top Sponsors
Cancer Research UK 2 trials
OriCell Therapeutics Co., Ltd. 1 trial
University of Michigan Rogel Cancer Center 1 trial
Pierre Fabre Medicament 1 trial
Azienda Ospedaliero-Universitaria di Parma 1 trial

Recruiting Clinical Trials

NCT07440290 Phase 2, Phase 3
Recruiting
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
View Trial →
NCT06271252 Phase 1
Recruiting
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Enrollment
81 pts
Location
United States
Sponsor
OriCell Therapeutics Co., Ltd.
View Trial →
NCT05770544 Phase 2, Phase 3
Recruiting
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
View Trial →
NCT04858256 Phase 2
Recruiting
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
Enrollment
100 pts
Location
United States
Sponsor
University of Michigan Rogel C...
View Trial →
NCT03394365 Phase 3
Recruiting
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Enrollment
115 pts
Location
United States, Austr...
Sponsor
Pierre Fabre Medicament
View Trial →
NCT07445984
Recruiting
Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
Enrollment
250 pts
Location
Italy
Sponsor
Azienda Ospedaliero-Universita...
View Trial →

Related Conditions

neoplasms by histologic type (3) haematological malignancy (2) malignant neoplasm (2) neoplasms by site (2) cancer (2) glioma (2) multiple myeloma (2) solid tumour (2) gastrointestinal cancer (1) non melanoma skin cancer nmsc (1) langerhans cell histiocytosis lch (1) erdheim chester disease (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology